Journal
GASTROENTEROLOGY
Volume 156, Issue 2, Pages 510-524Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2018.09.051
Keywords
Tumor; Human; Checkpoint Inhibitor
Categories
Funding
- Intramural Research Program of the National Cancer Institute, National Institutes of Health [ZIA-BC 011343]
- intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
- National Cancer Institute, National Institutes of Health [R01 CA164335]
- NATIONAL CANCER INSTITUTE [R01CA164335, ZIABC011343] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Treatment options for patients with hepatocellular carcinoma are rapidly changing based on positive results from phase 3 trials of targeted and immune-based therapies. More agents designed to target specific pathways and immune checkpoints are in clinical development. Some agents have already been shown to improve outcomes of patients with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the Food and Drug Administration or have been recently approved. We summarize the targeted and immune-based agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these strategies for liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available